HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?

AbstractOBJECTIVE:
In patients with ischemic cardiomyopathy and a substantial amount of dysfunctional but viable myocardium, myocardial revascularization may improve left ventricular ejection fraction. The aim of this study was to evaluate why not all patients with a substantial amount of viable tissue recover in function after revascularization.
METHODS:
A total of 118 consecutive patients with a depressed left ventricular ejection fraction (on average 29% +/- 6%) due to chronic coronary artery disease underwent myocardial revascularization. Before revascularization all patients underwent dobutamine stress echocardiography to assess regional dysfunction, left ventricular volumes, and myocardial viability as well as radionuclide ventriculography to determine the left ventricular ejection fraction. Next, 3 to 6 months after revascularization, the left ventricular ejection fraction and regional contractile function were reassessed. Improvement of left ventricular ejection fraction > or = 5% following revascularization was considered clinically significant.
RESULTS:
Dobutamine stress echocardiography revealed that 489 (37%) of the 1329 dysfunctional segments were viable. A total of 61 (52%) patients had a substantial amount of viable myocardium (> or = 4 viable segments). In these 61 patients the global function was expected to recover > or = 5% after revascularization. However, left ventricular ejection fraction did not improve in 20 (33%) of 61 patients despite the presence of substantial viability. Clinical characteristics and echocardiographic data were comparable between patients with and without improvement. However, patients without improvement had considerably larger end systolic volumes (153 +/- 41 mL vs 133 +/- 46 mL, P =.007). The likelihood of recovery of global function decreased proportionally with the increase of end systolic volume (P <.001, R = 0.43, n = 61). Receiver operating characteristic curve analysis demonstrated that an end systolic volume > or = 140 mL had the highest sensitivity/specificity to predict the absence of global recovery.
CONCLUSIONS:
In patients with ischemic cardiomyopathy not only the amount of dysfunctional but viable myocardium but also the extent of left ventricular remodeling determines the improvement in function following myocardial revascularization. Patients with a high end systolic volume due to left ventricular remodeling have a decreased likelihood of improvement of global function.
AuthorsArend F L Schinkel, Don Poldermans, Vittoria Rizzello, Jean-Louis J Vanoverschelde, Abdou Elhendy, Eric Boersma, Jos R T C Roelandt, Jeroen J Bax
JournalThe Journal of thoracic and cardiovascular surgery (J Thorac Cardiovasc Surg) Vol. 127 Issue 2 Pg. 385-90 (Feb 2004) ISSN: 0022-5223 [Print] United States
PMID14762345 (Publication Type: Comparative Study, Evaluation Study, Journal Article)
Topics
  • Aged
  • Cardiomyopathies (diagnostic imaging, physiopathology)
  • Coronary Stenosis (complications, physiopathology, surgery)
  • Echocardiography
  • Echocardiography, Stress
  • Female
  • Follow-Up Studies
  • Heart Failure (diagnostic imaging, physiopathology, surgery)
  • Heart Ventricles (diagnostic imaging, physiopathology)
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardial Contraction (physiology)
  • Myocardial Infarction (physiopathology, surgery)
  • Myocardial Ischemia (diagnostic imaging, physiopathology, surgery)
  • Myocardial Revascularization
  • Myocardium (pathology)
  • Predictive Value of Tests
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Statistics as Topic
  • Stroke Volume (physiology)
  • Treatment Outcome
  • Ventricular Dysfunction, Left (diagnostic imaging, etiology, physiopathology, surgery)
  • Ventricular Remodeling (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: